Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data
— Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data
by Judy George, Deputy Managing Editor, MedPage Today
July 27, 2026
• 3 min read
FDA scientists said that investigational deramiocel, a stem cell treatment for Duchenne muscular dystrophy, did not meet its primary endpoint in a phase III trial, despite data presented at the American Academy of Neurology (AAN) annual meeting to the contrary.
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics
FDA panel recommends easing restrictions on several peptides, including BPC-157
FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157
FDA panel endorses broader use of certain peptides
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist…
FDA staff say Capricor's deramiocel fails to show clear efficacy for Duchenne, tanking shares 65%+ ahead of this week's adcomm…
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July…
A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make…
